Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × HBI-8000 × Gastrointestinal × Clear all
NCT05770882 2025-03-11

Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)

Great Novel Therapeutics Biotech & Medicals Corporation

Phase 1/2 Terminated
7 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05281276 2024-12-20

Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)

Taipei Medical University Shuang Ho Hospital

Phase 1 Terminated
9 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡